Prudential Financial
BIOL

Prudential Financial’s Biolase, Inc. BIOL Stock Holding History

Prudential Financial’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-588
Closed -$16.5K – 2742
2023
Q1 		$16.5K Buy
588
+166
+39% +$8.08K ﹤0.01% 2569
2022
Q4 		$27.4K Buy
+422
New +$60.7K ﹤0.01% 2551

Other funds holding BIOL

Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Prudential Financial's BIOL Position: Q2 2023 in Review

Prudential Financial sold out of Biolase, Inc. (BIOL) in Q2 2023, closing a stake of 588 shares — an estimated $16.5K sold.

Prudential Financial first reported a position in BIOL in Q4 2022 and held it in 2 quarters. The position peaked at $27.4K in Q4 2022. 25 funds tracked by Wall St. Rank hold BIOL as of Q2 2023.

  • Prudential Financial reported no remaining Biolase, Inc. position as of Q2 2023 after selling out during the quarter.
  • Prudential Financial sold 588 Biolase, Inc. shares in Q2 2023, an estimated $16.5K.
  • Prudential Financial first reported a position in Biolase, Inc. in Q4 2022 and held it in 2 quarters.
  • Prudential Financial's Biolase, Inc. position peaked at $27.4K in Q4 2022.
  • 25 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2023.

Based on Prudential Financial's 13F filing for Q2 2023, filed 11 Aug 2023.